07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Advancell, Helsinn deal

Advancell granted Helsinn exclusive, worldwide rights to develop and commercialize ATH008. The undisclosed topical cream is in development to treat palmoplantar erythrodysesthesia syndrome (PPES) and hand-foot skin reactions (HFSR), which are painful cutaneous reactions...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

ATH008: Phase IIb started

Advancell began a double-blind, placebo-controlled, European Phase IIb trial to evaluate twice-daily 1%, 3% and 8% ATH008 in up to 100 patients with PPES secondary to capecitabine monotherapy. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets...